CDSCO expert panel recommends Covaxin be moved out of 'clinical trial mode'
An expert panel of India's central drugs authority on Wednesday recommended granting emergency use authorisation to Bharat Biotech's indigenously developed Covaxin while removing the condition for the vaccine to be administered in 'clinical trial mode', official sources said.
You Might Like
💡 newsR Knowledge: Other News Mentions
Import licences for foreign vaccine in 3 days, says government“The CDSCO (Central Drugs Standard Control Organisation) will process applications for registration certificate (registration of oversees manufacturing site..
Health ministry issues regulatory pathways for foreign-produced Covid-19 vaccinesThe Central Drugs Standards Control Organisation (CDSCO) headed by Drugs Controller General of India (DCGI) has explained that it prepare detailed guidelines..
Use entire national capacity to step up Covid vaccine production, PM tells officialsThe PM’s directive came at a review meeting on the Covid situation on Saturday a day after he had overseen an assessment of oxygen supplies and production and..
Covaxin production to be increased to 100 million doses per month by September 2021: CentreUnion health minister Harsh Vardhan said financial support is being provided to four manufacturers to expand Covaxin vaccine production.
India to increase Covaxin production to 100 million doses per month by SeptemberThe Union government on Friday said it will amp up the production of the indigenously developed Covaxin vaccine to 100 million doses per month by September. As..
Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin
Credit: ANI Duration: 01:14Published
Even as Covid vaccine demand rises, firms may take some weeks to up productionIndications are that India’s vaccine production is expected to be limited for a few more weeks though a step-up is expected as Serum Institute of India and..
Related videos from verified sources
Related news from verified sources